AstraZeneca to build manufacturing facility in Ireland

Article by Amanda Doyle

ASTRAZENECA has announced that it is planning to build a new active pharmaceutical ingredient (API) manufacturing facility in Ireland.

The next-generation API manufacturing facility for small molecules will be located at the Alexion Campus in College Park, Dublin. It will facilitate late-stage development and early commercial supply with a planned investment of US$360m. The investment in the facility is expected to significantly reduce commercial lead times and costs, as well as develop more sustainable manufacturing processes. It will have the capability to manufacture a wide range of medicines, including new modalities such as antibody drug conjugates and oligonucleotides.

Pam Cheng, AstraZeneca’s Executive Vice President, Global Operations and IT, said: “The future manufacturing of APIs for our medicines includes compounds with highly complex synthesis, requiring next generation technologies and capabilities that can respond quickly and nimbly to rapidly-changing clinical and commercial needs. This significant investment will ensure the AstraZeneca supply network is fit for the future.”

Micheál Martin, Taoiseach, said: “I warmly welcome today’s announcement from AstraZeneca that it is to establish its first ever manufacturing facility in Ireland. This […] investment represents a significant commitment to Ireland and will see 100 jobs being created. In choosing Ireland as the location for its new next-generation active pharmaceutical ingredient manufacturing facility, AstraZeneca joins the very strong and successful network of global life sciences companies we have in Ireland. I wish them every success with their operations here.”

Article by Amanda Doyle

Staff Reporter, The Chemical Engineer

Recent Editions

Catch up on the latest news, views and jobs from The Chemical Engineer. Below are the four latest issues. View a wider selection of the archive from within the Magazine section of this site.